UAE Frontline Healthcare Workers Set Guinness World Record for ‘Most Nationalities Carrying a Banner’ in Solidarity with the Nation • In spite of rain, Burjeel Holdings’ frontline healthcare workers from 64 nationalities united under one banner in a powerful tribute to the UAE during the Group’s annual sports event, Burjeel Games • Carrying a banner … Continue reading UAE Healthcare Workers Set Guinness Record for Unity
Category: Health Care
A beating heart, restored at Medcare: How a 50 year old patient became the face of a cardiac breakthrough in UAE
Medcare Hospital Sharjah performed the Volt™ Pulsed-Field Ablation procedure, a cutting-edge technology designed to target the origin of irregular heart signals while safeguarding adjacent healthy tissue. Sharjah, UAE – April 8th, 2026: Imagine a life where your heart is always racing, fluttering, and unable to find a steady rhythm. For a 50-year-old Egyptian expat in Sharjah, … Continue reading A beating heart, restored at Medcare: How a 50 year old patient became the face of a cardiac breakthrough in UAE
Burjeel Launches Tajmeel Flagship Clinic in Jumeirah with Focus on Advanced and Regenerative Aesthetic Services
The clinic, inaugurated by H.E. Dr. Thani bin Ahmed Al Zeyoudi, blends medical precision with a deeply individualized experience in Dubai’s evolving aesthetics landscape. Dubai: Tajmeel Clinic, the premium cosmetics and aesthetics brand under Burjeel Holdings, has unveiled its flagship destination in Jumeirah, marking a significant milestone in Tajmeel’s expansion across Dubai’s competitive aesthetics and dental … Continue reading Burjeel Launches Tajmeel Flagship Clinic in Jumeirah with Focus on Advanced and Regenerative Aesthetic Services
3-3-3 grounding rule suggested as a healthy calming technique for young children
Age-appropriate communication styles and coping strategies are advised to manage stress and anxiety 1 April 2026; Ras Al Khaimah, UAE – As regional tensions and constant news updates create a sense of uncertainty for many families, mental health experts are advising parents to pay close attention to how children are responding emotionally and to use age-appropriate … Continue reading 3-3-3 grounding rule suggested as a healthy calming technique for young children
FDA Approves Awiqli®: Once-Weekly Basal Insulin for Type 2 Diabetes
Dubai, 30 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences for adults living with type 2 diabetes. The approval is based on results from the ONWARDS phase 3a programme in type-2-diabetes for once-weekly Awiqli® injection, which comprises four randomised, active-controlled, treat-to- target trials in approximately 2,680 adults with uncontrolled type 2 diabetes, used in combination with a mealtime insulin or in combination with common oral anti-diabetic agents and/or GLP-1 receptor agonists. The clinical programme evaluated once-weekly Awiqli® vs daily basal insulin and demonstrated efficacy in the primary endpoint of HbA1c reduction across the ONWARDS pivotal clinical trial programme in adults with type 2 diabetes. Across ONWARDS trials, the safety profile of Awiqli® was overall consistent with the daily basal insulin class. “The Awiqli® approval reflects Novo Nordisk’s ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes. As the first FDA-approved, once-weekly basal insulin for adults with type 2 diabetes, it offers an important new treatment option. At a time when parts of the industry are stepping back from insulin, we are reaffirming our commitment - continuing to invest in innovation, access, and supply for the millions of patients who rely on insulin every day,” said Mike Doustdar, president and CEO of Novo Nordisk. Novo Nordisk expects to launch Awiqli® in the FlexTouch® device in the US in the second half of 2026. Awiqli® is now approved in the US, EU, and 13 additional countries, with market-specific indications for diabetes.
uaenews4u.com 